{"product_id":"abcam-ab275504","title":"Abcam, ab275504, Human VCAM1 knockout A549 cell lysate","description":"\u003cp\u003eSize: 1Kit\u003cbr\u003e\nVCAM1 KO cell lysate available now. KO validated by Immunocytochemistry, Western blot. Free of charge wild type control included. Knockout achieved by using CRISPR\/Cas9, Homozygous: 4 bp deletion in exon 2.\u003cbr\u003e\nKey facts\u003cbr\u003e\nCell type:A549,\u003cbr\u003e\nSpecies or organism:Human,\u003cbr\u003e\nTissue:Lung,\u003cbr\u003e\nKnockout validation:Immunocytochemistry,Sanger Sequencing,Western blot,\u003cbr\u003e\nMutation description:Knockout achieved by using CRISPR\/Cas9, Homozygous: 4 bp deletion in exon 2,\u003cbr\u003e\nDisease:Carcinoma\u003c\/p\u003e\n\n\u003cp\u003eProduct details:\u003cbr\u003e\nKnockout cell lysate achieved by CRISPR\/Cas9.\u003cbr\u003e\nTreatments:\u003cbr\u003e\nHuman VCAM1 knockout A549 cell lysate - Untreated\u003cbr\u003e\nHuman wild-type A549 cell lysate - Untreated\u003cbr\u003e\nHuman VCAM1 knockout A549 cell lysate - TNF-a (10 ng\/ml, 16h)\u003cbr\u003e\nHuman wild-type A549 cell lysate - TNF-a (10 ng\/ml, 16h)\u003cbr\u003e\nREACH authorisation\u003cbr\u003e\nAbcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.\u003cbr\u003e\nIt is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.\u003cbr\u003e\nLysate preparation:\u003cbr\u003e\nOur lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).\u003cbr\u003e\nThis means that the protein of interest is denatured.\u003cbr\u003e\nIf you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.\u003cbr\u003e\nUser storage instructions:\u003cbr\u003e\nLyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.\u003cbr\u003e\nThis product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our\u003cbr\u003e\nlimited use license\u003cbr\u003e\npatent pages\u003c\/p\u003e\n\n\u003cp\u003eProperties and Storage Information:\u003cbr\u003e\nGene name-VCAM1, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Immunocytochemistry, Sanger Sequencing, Western blot, Zygosity-Homozygous, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C\u003c\/p\u003e\n\n\u003cp\u003eSupplementary Information:\u003cbr\u003e\nThis supplementary information is collated from multiple sources and compiled automatically.\u003cbr\u003e\nVCAM1 also known as vascular cell adhesion molecule 1 plays an important role in mediating adhesion and signal transduction. VCAM1 has an approximate molecular mass of 110 kDa. It is expressed on the surface of endothelial cells and can be upregulated by cytokines released during inflammation. The protein serves as a ligand for the integrin VLA-4 also known as α4β1 and contributes to the adhesion of leukocytes to endothelial cells.\u003cbr\u003e\nBiological function summary\u003cbr\u003e\nAdhesion molecules like VCAM1 participate in immune response by recruiting leukocytes to sites of inflammation. VCAM1 helps guide immune cells to directed locations where they perform defense activities. Although VCAM1 is not part of any known large protein complex its interaction with integrins facilitates the migration of immune cells across the endothelium and into tissue.\u003cbr\u003e\nPathways\u003cbr\u003e\nVCAM1 contributes significantly to the leukocyte extravasation process in inflammatory pathways. It plays a role in both the cytokine-cytokine receptor interaction pathway and the NF-kB signaling pathway which are essential for immune response and cell signaling. Through these pathways it interacts with proteins like ICAM1 and various chemokines helping to coordinate the immune cell movement through vascular tissue barriers.\u003cbr\u003e\nAbnormal regulation of VCAM1 links to various cardiovascular diseases such as atherosclerosis and inflammatory diseases like rheumatoid arthritis. The protein levels may increase in these conditions promoting excessive immune cell recruitment and tissue damage. VCAM1 also interfaces with other proteins like ICAM1 in these pathological states which together contribute to the progression and severity of these diseases.\u003c\/p\u003e","brand":"Abcam","offers":[{"title":"Default Title","offer_id":46845086761129,"sku":"ab275504","price":0.99,"currency_code":"USD","in_stock":true}],"url":"https:\/\/iright.com\/es\/products\/abcam-ab275504","provider":"Iright","version":"1.0","type":"link"}